Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Availability:

NEW WEAPONS AGAINST SARS-CoV-2 AND HIV

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 13 of 13
INTRODUCTION OF SPEAKERS (PART I)
Joseph J Eron
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
BAMLANIVIMAB PREVENTS COVID-19 MORBIDITY AND MORTALITY IN NURSING-HOME SETTING   (ABSTRACT 121)
Myron S Cohen
The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
BAMLANIVIMAB+ETESEVIMAB FOR TREATMENT OF COVID-19 IN HIGH-RISK AMBULATORY PATIENTS   (ABSTRACT 122)
Michael Dougan
Massachusetts General Hospital, Boston, MA, USA
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
CASIRIVIMAB WITH IMDEVIMAB ANTIBODY COCKTAIL FOR COVID-19 PREVENTION: INTERIM RESULTS   (ABSTRACT 123)
Meagan P. O'Brien
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
POTENT NEUTRALIZING ANTIBODIES FOR SEVERE COVID-19: A RANDOMIZED CLINICAL TRIAL   (ABSTRACT 124)
Carlijn Jordans
Erasmus Medical Center, Rotterdam, Netherlands
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
LIVE QUESTIONS AND ANSWERS (PART I) WITH PRESENTERS AND ATTENDEES
Myron S Cohen
The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Joseph J Eron
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Michael Dougan
Massachusetts General Hospital, Boston, MA, USA
Meagan P. O'Brien
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
Carlijn Jordans
Erasmus Medical Center, Rotterdam, Netherlands
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
INTRODUCTION OF SPEAKERS (PART II)
Douglas D Richman
University of California San Diego, La Jolla, CA, USA
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
ESTIMATING WITHIN-HOST R0 FOR SARS-COV-2 AND IMPLICATIONS FOR ANTIVIRAL THERAPY   (ABSTRACT 125)
Ruian Ke
Los Alamos National Laboratory, Los Alamos, USA
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
PHASE IIA PROOF-OF-CONCEPT TRIAL OF NEXT-GENERATION MATURATION INHIBITOR GSK3640254   (ABSTRACT 126)
Christoph Spinner
Technical University of Munich School of Medicine, Munich, Germany
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
POTENT ANTIVIRAL ACTIVITY OF LENACAPAVIR IN PHASE 2/3 IN HEAVILY ART-EXPERIENCED PWH   (ABSTRACT 127)
Sorana Segal-Maurer
New York-Presbyterian Queens, Flushing, NY, USA
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
ACTIVITY AND RESISTANCE CHARACTERIZATION OF THE HIV CAPSID INHIBITOR LENACAPAVIR   (ABSTRACT 128)
Laurie VanderVeen
Gilead Sciences, Inc, Foster City, CA, USA
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
RESISTANCE PROFILE OF MK-8507, A NOVEL NNRTI SUITABLE FOR WEEKLY ORAL HIV TREATMENT   (ABSTRACT 129)
Tracy Lauren Diamond
Merck & Co, Inc, West Point, PA, USA
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
LIVE QUESTIONS AND ANSWERS (PART II) WITH PRESENTERS AND ATTENDEES
Ruian Ke
Los Alamos National Laboratory, Los Alamos, USA
Douglas D Richman
University of California San Diego, La Jolla, CA, USA
Christoph Spinner
Technical University of Munich School of Medicine, Munich, Germany
Sorana Segal-Maurer
New York-Presbyterian Queens, Flushing, NY, USA
Laurie VanderVeen
Gilead Sciences, Inc, Foster City, CA, USA
Tracy Lauren Diamond
Merck & Co, Inc, West Point, PA, USA
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 13 of 13